Tania Gudu1,2, Uta Kiltz1,2, Maarten de Wit1,2, Tore Kristian Kvien1,2, Laure Gossec3,4. 1. From the Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Research Center of Rheumatic Diseases, Sf. Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania; Rheumazentrum Ruhrgebiet, Herne and Ruhr-University Bochum, Herne, Germany; Patient Research Partner, People with Arthritis/Rheumatism in Europe (EULAR PARE), Zurich, Switzerland; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. 2. T. Gudu, MD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, and Research Center of Rheumatic Diseases, Sf. Maria Hospital, University of Medicine and Pharmacy Carol Davila; U. Kiltz, MD, Rheumazentrum Ruhrgebiet, Herne and Ruhr-University Bochum; M. de Wit, PhD, Patient Research Partner, EULAR PARE; T.K. Kvien, MD, PhD, Professor of Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital; L. Gossec, MD, PhD, Professor of Rheumatology, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology. 3. From the Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Research Center of Rheumatic Diseases, Sf. Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania; Rheumazentrum Ruhrgebiet, Herne and Ruhr-University Bochum, Herne, Germany; Patient Research Partner, People with Arthritis/Rheumatism in Europe (EULAR PARE), Zurich, Switzerland; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. laure.gossec@aphp.fr. 4. T. Gudu, MD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, and Research Center of Rheumatic Diseases, Sf. Maria Hospital, University of Medicine and Pharmacy Carol Davila; U. Kiltz, MD, Rheumazentrum Ruhrgebiet, Herne and Ruhr-University Bochum; M. de Wit, PhD, Patient Research Partner, EULAR PARE; T.K. Kvien, MD, PhD, Professor of Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital; L. Gossec, MD, PhD, Professor of Rheumatology, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology. laure.gossec@aphp.fr.
Abstract
OBJECTIVE: The effect of a disease can be categorized by a standardized reference system: the International Classification of Functioning, Disability and Health (ICF). The objective was to map the effect of psoriatic arthritis (PsA) from the patient's perspective to the ICF. METHODS: A systematic literature review was performed. Qualitative publications reporting domains of impact important for patients with PsA were identified using the following terms: ("psoriatic arthritis") AND ("quality of life" OR "impact"). Meaningful concepts were extracted from the publications, grouped into domains and linked to the ICF categories. The number of concepts linked to each ICF category and to each ICF level was calculated. The number of concepts not linkable was also calculated. RESULTS: Eleven studies (13 articles) were included in the analysis. Twenty-five domains of impact were cited, of which the ability to work/volunteer and social participation were the most cited (both by 10 studies). In total, 258 concepts were identified, of which 217 could be linked to 136 different ICF categories; 41 concepts, mostly personal factors, could not be precisely linked. The most represented ICF component was activities and participation (42.6%) rather than body structures (10.3%) or body functions (29.4%). Ten studies (90.9%) reported impairments in the ability to work/volunteer and social participation, and 7 (63.6%) reported leisure activities, family and intimacy, pain, skin problems, and body image. CONCLUSION: PsA widely affects all aspects of patients' lives, in particular aspects related to activities and participation. The ICF is a useful approach for the classification of disease effect.
OBJECTIVE: The effect of a disease can be categorized by a standardized reference system: the International Classification of Functioning, Disability and Health (ICF). The objective was to map the effect of psoriatic arthritis (PsA) from the patient's perspective to the ICF. METHODS: A systematic literature review was performed. Qualitative publications reporting domains of impact important for patients with PsA were identified using the following terms: ("psoriatic arthritis") AND ("quality of life" OR "impact"). Meaningful concepts were extracted from the publications, grouped into domains and linked to the ICF categories. The number of concepts linked to each ICF category and to each ICF level was calculated. The number of concepts not linkable was also calculated. RESULTS: Eleven studies (13 articles) were included in the analysis. Twenty-five domains of impact were cited, of which the ability to work/volunteer and social participation were the most cited (both by 10 studies). In total, 258 concepts were identified, of which 217 could be linked to 136 different ICF categories; 41 concepts, mostly personal factors, could not be precisely linked. The most represented ICF component was activities and participation (42.6%) rather than body structures (10.3%) or body functions (29.4%). Ten studies (90.9%) reported impairments in the ability to work/volunteer and social participation, and 7 (63.6%) reported leisure activities, family and intimacy, pain, skin problems, and body image. CONCLUSION: PsA widely affects all aspects of patients' lives, in particular aspects related to activities and participation. The ICF is a useful approach for the classification of disease effect.
Entities:
Keywords:
EMOTIONAL FUNCTIONS; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH (ICF); PATIENT PERSPECTIVE; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SOCIETAL BURDEN
Authors: Tomas Mlcoch; Jan Tuzil; Liliana Sedova; Jiri Stolfa; Monika Urbanova; David Suchy; Andrea Smrzova; Jitka Jircikova; Tereza Hrnciarova; Karel Pavelka; Tomas Dolezal Journal: Patient Date: 2018-06 Impact factor: 3.883